NCT01923389View on ClinicalTrials.gov

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
OTHER

Placebo

0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.

DRUG

100 mg PF-05231023

100 mg IV infusion twice a week for 4 weeks

Trial Locations (2)

32803

Pfizer Investigational Site, Orlando

32804

Pfizer Investigational Site, Orlando

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01923389 - Multiple Dose Study Of PF-05231023 In Obese Adult Subjects | Biotech Hunter | Biotech Hunter